MTIF have developed an integrated set of capabilities which cover core discovery techniques utilising both primary derived human and animal cells as well as immortalised cell lines in static and flow bioreactors. including cell isolation, purification, characterisation, differentiation, enrichment, and expansion of both autologous and allogeneic cell therapies.

 

Collaborate with MTIF to Accelerate your cell therapy development. We are here to offer facilities and equipment, together with personnel expertise to support cell therapy development when in-house resources are limited

Cell, Molecule and Material Interaction

Cell, Molecule and Material Interaction is an essential component in the development of the next generation therapies including Advanced Therapy Medicinal Products (ATMPs). Our capabilities cover core discovery techniques utilising both primary derived human and animal cells as well as immortalised cell lines in static and flow bioreactors. We utilise primary, terminally differentiated and progenitor cell sources to evaluate biocompatibility. MTIF is able to develop in vitro platforms such as 3D tissue analogues, enabling the development of cellular models using tissue-on-a-chip, Clustered Regularly Interspaced Short Palindromic Repeats – associated protein-9 nuclease (CRISPR/Cas9) or combinations of both approaches. We are able to fully characterise materials including testing to IS010993